Multisystem inflammatory syndrome in children (MIS-C) is a novel, 
life-threatening hyperinflammatory condition that develops in children a few 
weeks after infection with severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2). This disease has created a diagnostic challenge due to overlap 
with Kawasaki disease (KD) and KD shock syndrome. The majority of patients with 
MIS-C present with the involvement of at least four organ systems, and all have 
evidence of a marked inflammatory state. Most patients show an increase in the 
level of at least four inflammatory markers (C-reactive protein, neutrophil 
count, ferritin, procalcitonin, fibrinogen, interleukin-6, and triglycerides). 
Therapy is primarily with immunomodulators, suggesting that the disease is 
driven by post-infectious immune dysregulation. Most patients, even those with 
severe cardiovascular involvement, recover without sequelae. Since coronary 
aneurysms have been reported, echocardiographic follow-up is needed.Further 
study is needed to create uniform diagnostic criteria, therapy, and follow-up 
protocols.